ArticleJournal of market access & health policy2018

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK.

Emilie Clay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.